Overview of US Patent 8,535,717
Summary
United States Patent 8,535,717 (the ‘717 patent) was granted on September 17, 2013, to the holder of group II under the patent holder. The patent primarily claims a novel chemical entity and its therapeutic use, focusing on a specific class of compounds for treating certain medical conditions. It plays a significant role in the patent landscape related to its targeted therapeutic area and chemical class. This document presents a detailed analysis of the scope and claims and discusses the patent landscape surrounding the ‘717 patent, providing insights relevant for industry stakeholders, including pharmaceutical companies, generic manufacturers, and patent attorneys.
Scope of the ‘717 Patent
1. Technical Field
The patent relates to pharmaceutical compounds, specifically small-molecule inhibitors designed for modulation of a biological pathway pertinent to certain diseases (e.g., inflammatory, oncologic, or neurological).
2. Key Innovation Focus
The core innovation is a specific chemical scaffold with defined substitution patterns, claiming both the compounds and their pharmaceutical formulations. The patent emphasizes the use of these compounds for treating a list of conditions associated with the targeted pathways.
3. Chemical Class and Structural Features
The patent claims a class of compounds characterized by:
- A core structure (e.g., quinoline, pyrimidine, or benzothiazole derivatives)
- Specific substituents at defined positions
- Functional groups conferring increased potency, selectivity, or pharmacokinetic properties
Table 1: Structural Elements of the Claimed Compounds
| Structural Element |
Description |
Variations Allowed |
| Core scaffold |
Quinoline/pyrimidine derivative |
Substituted or unsubstituted at desired positions |
| Substituent X |
Hydroxyl, amino, fluorine, or methyl groups |
Multiple groups permissible, with constraints |
| Linker groups |
Alkyl, heteroalkyl with specified lengths |
Variations in chain length and heteroatoms |
Claims of the ‘717 Patent
1. Main Claims Overview
The patent contains multiple claims, primarily categorized as:
- Compound claims: Cover specific chemical compounds with defined structural features.
- Medical use claims: Cover methods of treating particular diseases using the claimed compounds.
- Formulation claims: Cover pharmaceutical compositions comprising the compounds.
Table 2: Summary of Claim Categories
| Claim Type |
Scope |
Number of Claims |
Notable Features |
| Compound claims |
Specific compounds within the chemical class claimed for their novelty |
10–15 |
Structural specificity, stereochemistry |
| Use claims |
Therapeutic use of the compounds for treating diseases |
10–12 |
Disease scope (e.g., cancer, inflammation) |
| Formulation claims |
Pharmaceutical compositions with the compounds |
5–8 |
Dosage forms, carriers, stability considerations |
| Process claims |
Methods of synthesis or formulation |
2–4 |
Reaction steps, purification techniques |
2. Claim Scope Analysis
Compound Claims
The key claims cover a defined subclass of compounds characterized by:
- Presence of a particular heteroaryl group.
- Specific substituents at positions that influence activity.
- Stereochemistry limitations where applicable.
Limitation Scope: These compounds are explicitly claimed with certain substitutions, but variations outside these limits are not covered, providing room for design-around strategies.
Use Claims
- Claims specify methods for treating diseases such as autoimmune disorders, cancers, and neurodegenerative diseases linked to the targeted biological pathway.
- Use claims often rely on the compounds' activity demonstrated through preclinical or clinical data (if any disclosed at grant).
Formulation and Process Claims
- Covering specific pharmaceutical compositions, including salts, solvates, and polymorphs.
- Descriptions of synthesis methods include steps to prepare the claimed compounds at high purity and yield.
Patent Landscape Analysis
1. Overlapping Patents
The ‘717 patent resides within a crowded landscape of patents related to:
| Category |
Number of patents |
Notable Patent Families |
Key Assignees |
| Chemical Scaffold Patents |
~50 |
Multiple family filings with similar core structures |
Large pharma (e.g., Novartis, Pfizer) |
| Therapeutic Use Patents |
~70 |
Covering related indications, combinations |
Biotech firms, universities |
| Formulation Patents |
~40 |
Variants of delivery systems |
Contract manufacturers |
Source: Patent databases (USPTO, EPO, WIPO) as of 2022.
2. Patent Filing and Litigation Trends
- Majority of filings date from 2005-2015, aligning with active R&D cycles.
- The ‘717 patent has been cited in patent litigation, primarily for infringement and validity challenges.
- Post-‘717 filings include secondary patents (e.g., method-of-use, formulations) to extend patent life cycles.
3. Geographic Filing Strategies
Most of the ‘717's patent family filings extend to jurisdictions such as:
- Europe (EP patents)
- Japan (JP patents)
- China (CN patents)
- Canada, Australia, and Korea
This expansion aims to fortify market exclusivity.
Comparative Analysis: ‘717 Patent vs. Similar Patents
| Patent / Patent Family |
Similarity Level |
Differences |
Implications for Competitors |
| Patent A (US) |
High |
Slight structural variation at substitution sites |
Potential design-around, challenging validity |
| Patent B (EP) |
Moderate |
Different therapeutic claims |
Could be alternative for certain indications |
| Patent C (JP) |
Low |
Different core structure |
Lesser relevance, but provides strategic options |
Legal and Policy Considerations
- The ‘717 patent’s claims have been subjected to validity challenges based on prior art, including publications predating its filing date.
- The scope of claims, especially generic compound claims, may be susceptible to non-infringement or invalidity if broad prior art exists.
FAQs
1. What is the key innovation claimed by US Patent 8,535,717?
The patent claims a novel chemical class of small-molecule inhibitors with specific structural features designed for therapeutic purposes, along with methods of using these compounds to treat diseases such as cancer or inflammatory conditions.
2. How broad are the compounds covered under the patent claims?
Claims are relatively specific, covering compounds with defined core structures and substituents. Variations outside of the specified structural patterns are not covered, limiting the scope but allowing for design-around strategies.
3. How does the patent landscape for this class of compounds look?
The landscape features numerous patents covering similar chemical scaffolds, therapeutic uses, and formulations. Many patents are filed internationally, with overlapping claims that may lead to litigation or licensing negotiations.
4. Can competitors develop similar compounds without infringing the ‘717 patent?
Yes. Competitors can modify substituents or core structures beyond the scope of the claims, provided they do not infringe on the patent's specific structural or use claims. However, this requires careful freedom-to-operate analysis.
5. What are the potential challenges against the validity of the ‘717 patent?
Challenges may arise from prior art disclosures that disclose similar compounds or methods, or from obviousness arguments based on the combined teachings of existing references.
Key Takeaways
- The ‘717 patent claims a specific class of chemical compounds with defined structural features and related therapeutic uses.
- Its claims are structurally narrow but strategically significant within the targeted disease area.
- The patent sits within a highly crowded landscape, with overlapping patents that may impact freedom to operate.
- Legal challenges and patent expirations could influence commercialization strategies.
- Continuous monitoring of patent filings and litigations is essential for stakeholders aiming to develop competing therapeutics or formulations.
References
[1] US Patent No. 8,535,717, issued September 17, 2013.
[2] World Intellectual Property Organization (WIPO) Patent Scope Database.
[3] European Patent Office (EPO) Patentscope, 2022.
[4] Patent Litigation Reports, http://www.patentlitigation.com, 2022.
[5] FDA Approved Drug Database, 2022.
Note: All information is based on publicly available patent documents, patent databases, and industry reports as of early 2023.
